TY  - JOUR
AU  - Rothenbacher, Dietrich
AU  - Rehm, Martin
AU  - Iacoviello, Licia
AU  - Costanzo, Simona
AU  - Tunstall-Pedoe, Hugh
AU  - Belch, Jill J F
AU  - Söderberg, Stefan
AU  - Hultdin, Johan
AU  - Salomaa, Veikko
AU  - Jousilahti, Pekka
AU  - Linneberg, Allan
AU  - Sans, Susana
AU  - Padró, Teresa
AU  - Thorand, Barbara
AU  - Meisinger, Christa
AU  - Kee, Frank
AU  - McKnight, Amy Jayne
AU  - Palosaari, Tarja
AU  - Kuulasmaa, Kari
AU  - Waldeyer, Christoph
AU  - Zeller, Tanja
AU  - Blankenberg, Stefan
AU  - Koenig, Wolfgang
TI  - Contribution of cystatin C- and creatinine-based definitions of chronic kidney disease to cardiovascular risk assessment in 20 population-based and 3 disease cohorts: the BiomarCaRE project.
JO  - BMC medicine
VL  - 18
IS  - 1
SN  - 1741-7015
CY  - Heidelberg [u.a.]
PB  - Springer
M1  - DKFZ-2020-02419
SP  - 300
PY  - 2020
N1  - #EA:C070#
AB  - Chronic kidney disease has emerged as a strong cardiovascular risk factor, and in many current guidelines, it is already considered as a coronary heart disease (CHD) equivalent. Routinely, creatinine has been used as the main marker of renal function, but recently, cystatin C emerged as a more promising marker. The aim of this study was to assess the comparative cardiovascular and mortality risk of chronic kidney disease (CKD) using cystatin C-based and creatinine-based equations of the estimated glomerular filtration rate (eGFR) in participants of population-based and disease cohorts.The present study has been conducted within the BiomarCaRE project, with harmonized data from 20 population-based cohorts (n = 76,954) from 6 European countries and 3 cardiovascular disease (CVD) cohorts (n = 4982) from Germany. Cox proportional hazards models were used to assess hazard ratios (HRs) for the various CKD definitions with adverse outcomes and mortality after adjustment for the Systematic COronary Risk Evaluation (SCORE) variables and study center. Main outcome measures were cardiovascular diseases, cardiovascular death, and all-cause mortality.The overall prevalence of CKD stage 3-5 by creatinine- and cystatin C-based eGFR, respectively, was 3.3
LB  - PUB:(DE-HGF)16
C6  - pmid:33161898
DO  - DOI:10.1186/s12916-020-01776-7
UR  - https://inrepo02.dkfz.de/record/165843
ER  -